CLOs on the Move

Patterson Dental

www.pattersondental.com

 
Patterson Companies, Inc (Patterson) is a value-added distributor serving three markets: North American dental supply, United States companion-pet (dogs, cats and other common household pets) and equine veterinary supply, and the worldwide rehabilitation
  • Number of Employees: 0-25
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Life Plus

Life Plus is a Batesville, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

StriVectin

Our mission is simple. Deliver the most high-performance skincare and haircare solutions powered by the latest clinical advances to transform the look of your skin and hair. At the center of every formula is patented, proprietary NIA-114 technology that supercharges StriVectin`s clinically proven, award winning products.

Enwave Optronics Inc

Enwave Optronics Inc is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CenterCare Inc

CenterCare Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.